Wolfgang Pfützner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wolfgang Pfützner has a total of 342 co-authors. Here are the top co-authors by number of shared publications:
- Christian Möbs
Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany
19 shared publications - Edzard Spillner
Immunological Biotechnology, Department of Biological and Chemical Engineering Aarhus University Aarhus Denmark
7 shared publications - Michèle Myriam Rauber
Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
6 shared publications Thilo Jakob
Department of Dermatology and Allergology Giessen University Medicine Giessen Germany
5 shared publications- Bettina Wedi
Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, Germany
4 shared publications J. Pickert
4 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in Allergology International
T cells in chronic spontaneous urticaria show skin-migratory capacity and endotype-specific differences
- 7 October 2026
- Published by Elsevier in Allergology International
Open AccessT cells in chronic spontaneous urticaria show skin-migratory capacity and endotype-specific differences
- 30 July 2026
- Published by Springer Nature in Die Dermatologie
- Vol. 77 (S3) , 132-133
72/m mit Exanthem im Badehosenbereich
- 30 July 2026
- Published by Springer Nature in Die Dermatologie
- Vol. 77 (S3) , 132-133
72/m mit Exanthem im Badehosenbereich
- Open Access
- 17 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Nanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen
Insect venoms can cause severe allergic reactions, including anaphylaxis, in sensitized individuals. In this study, we aim at preventing anaphylaxis mediated by the most abundant and dominant honeybee venom allergen phospholipase A2 (Api m 1) by blocking its interaction with allergic patient IgE. Therefore, we characterize selected Api m 1-specific nanobodies and identify two high-affinity binders with non-overlapping epitopes. Crystal structures of Api m 1/nanobody complexes reveal diametrically opposed epitopes, one of which involves the active site of Api m 1. Based on this background, we develop mono- and bispecific nanobody-human IgG1 Fc, which exhibits pronounced blocking of IgE binding and effector cell activation in blood samples from honeybee venom allergic patients and reduces systemic reactions in a mouse model of allergen-induced anaphylaxis. This work provides a rationale for using nanobody-based inhibitors to prevent Api m 1-mediated anaphylaxis in honeybee venom allergy.
- 17 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen
Insect venoms can cause severe allergic reactions, including anaphylaxis, in sensitized individuals. In this study, we aim at preventing anaphylaxis mediated by the most abundant and dominant honeybee venom allergen phospholipase A2 (Api m 1) by blocking its interaction with allergic patient IgE. Therefore, we characterize selected Api m 1-specific nanobodies and identify two high-affinity binders with non-overlapping epitopes. Crystal structures of Api m 1/nanobody complexes reveal diametrically opposed epitopes, one of which involves the active site of Api m 1. Based on this background, we develop mono- and bispecific nanobody-human IgG1 Fc, which exhibits pronounced blocking of IgE binding and effector cell activation in blood samples from honeybee venom allergic patients and reduces systemic reactions in a mouse model of allergen-induced anaphylaxis. This work provides a rationale for using nanobody-based inhibitors to prevent Api m 1-mediated anaphylaxis in honeybee venom allergy.
- Open Access
- 30 October 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (1) , 306-308
Successful tolerance induction by allergen immunotherapy in a patient with bee venom anaphylaxis under treatment with a Janus kinase 1/2 inhibitor
- 30 October 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (1) , 306-308
Open AccessSuccessful tolerance induction by allergen immunotherapy in a patient with bee venom anaphylaxis under treatment with a Janus kinase 1/2 inhibitor
- Open Access
- 17 August 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (8) , e70034
Booster Injection with Birch Pollen Extract Activates B‐Cellular Memory Responses in Patients Having Completed Allergen Immunotherapy
Allergen immunotherapy (AIT) of patients with IgE‐mediated allergy results in the synthesis of blocking IgG antibodies mediating allergen tolerance. However, as antibody concentrations wane after stopping AIT, tolerance may be lost. The impact of a single booster allergen application on B‐cellular memory in AIT‐treated birch pollen (BP)‐allergic patients was investigated. Twenty‐five patients with BP allergy who finished AIT 3–12 years ago received one allergen injection approximately 4 months prior to the next BP season. We determined peripheral Bet v 1‐specific IgG‐secreting cells (ASC) by ELISPOT analysis and BP‐specific IgG, IgG4, and IgE serum antibodies by ImmunoCAP, and the allergen‐blocking capacity of IgG/IgG4 antibodies by ELIFAB assay. Clinical responses were assessed by visual analog scales. Immunological findings were compared with the primary B cell response of 12 BP‐allergic patients receiving conventional AIT. Bet v 1‐specific ASC significantly increased 2–4 weeks after BP‐injection, accompanied by enhanced levels of both BP‐specific IgG/IgG4 antibodies and allergen‐blocking serum activity. Compared with conventional up‐dosing, a single booster vaccination led to a markedly stronger B cell response after 4 weeks. Allergen booster injection activates B‐cellular memory associated with blocking IgG/IgG4 antibodies, pointing to reinforcement of allergen tolerance after completion of AIT.
- 17 August 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (8) , e70034
Open AccessBooster Injection with Birch Pollen Extract Activates B‐Cellular Memory Responses in Patients Having Completed Allergen Immunotherapy
Allergen immunotherapy (AIT) of patients with IgE‐mediated allergy results in the synthesis of blocking IgG antibodies mediating allergen tolerance. However, as antibody concentrations wane after stopping AIT, tolerance may be lost. The impact of a single booster allergen application on B‐cellular memory in AIT‐treated birch pollen (BP)‐allergic patients was investigated. Twenty‐five patients with BP allergy who finished AIT 3–12 years ago received one allergen injection approximately 4 months prior to the next BP season. We determined peripheral Bet v 1‐specific IgG‐secreting cells (ASC) by ELISPOT analysis and BP‐specific IgG, IgG4, and IgE serum antibodies by ImmunoCAP, and the allergen‐blocking capacity of IgG/IgG4 antibodies by ELIFAB assay. Clinical responses were assessed by visual analog scales. Immunological findings were compared with the primary B cell response of 12 BP‐allergic patients receiving conventional AIT. Bet v 1‐specific ASC significantly increased 2–4 weeks after BP‐injection, accompanied by enhanced levels of both BP‐specific IgG/IgG4 antibodies and allergen‐blocking serum activity. Compared with conventional up‐dosing, a single booster vaccination led to a markedly stronger B cell response after 4 weeks. Allergen booster injection activates B‐cellular memory associated with blocking IgG/IgG4 antibodies, pointing to reinforcement of allergen tolerance after completion of AIT.
- Open Access
- 7 August 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , 86-98
Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus
Background: Pemphigus vulgaris (PV) is a CD4+ T-cell-dependent autoantibody-mediated blistering disease associated with human leucocyte antigen (HLA) class II molecules. IgG autoantibodies against the primary autoantigen desmoglein 3 (Dsg3), a desmosomal adhesion protein on epidermal keratinocytes, cause loss of epidermal cell adhesion. Objectives: To assess the clinical applicability of an innovative nanoparticle platform for the induction of immune tolerance exploiting the natural tolerance potential of liver sinusoidal endothelial cells. An open-label first-in-human study was conducted with TPM203, a mixture of four nanoparticle-coupled immunodominant Dsg3 T-cell peptides. Methods: The efficacy and mechanism of action of TPM203 were first tested in a humanized HLA-DRB1*0402-transgenic PV mouse model. In the clinical phase I trial, TPM203 was administered intravenously in patients with PV with no-to-moderate disease activity in single ascending and multiple doses (three doses of TPM203 two weeks apart). Primary endpoints included safety and tolerability. As a secondary endpoint, pharmacokinetics were assessed. Exploratory endpoints comprised changes in Dsg3-specific and bulk T- and B-cell frequencies, anti-Dsg3 IgG levels and autoantibody-induced keratinocyte dissociation. The trial was registered with EudraCT (2019-001727-12). Results: In the PV mouse model, two administrations of TPM203 significantly reduced anti-Dsg3 IgG. On the cellular level, TPM203 led to a significant decrease in CD4+ T cells in the spleen, accompanied by increased frequencies of regulatory T (Treg) cells. In the clinical trial, the 17 patients with PV enrolled across single- and multiple-dose groups did not experience any serious or severe adverse events, or treatment-related PV worsening. Pharmacokinetics confirmed rapid TPM203 clearance from the circulation. Significant TPM203-induced modulations in bulk lymphocyte subsets included an increase in Treg cells, and reductions in T helper 17.1 and CD27+ memory B cells, when dose groups were combined for analysis. Dsg3-specific T cells were found to be significantly reduced at week 8 following single administration of TPM203. Anti-Dsg3 IgG levels trended downward in the three lower single ascending dose groups, while IgG-induced keratinocyte-dissociating capacity was significantly reduced after multiple doses. Conclusions: Administered for the first time in humans, TPM203 was shown to be a safe and well-tolerated nanoparticle-based therapeutic approach with the potential to promote tolerance induction in PV, justifying further clinical development in this and other autoimmune diseases. An author video to accompany this article is available online.
- 7 August 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , 86-98
Open AccessSafety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus
Background: Pemphigus vulgaris (PV) is a CD4+ T-cell-dependent autoantibody-mediated blistering disease associated with human leucocyte antigen (HLA) class II molecules. IgG autoantibodies against the primary autoantigen desmoglein 3 (Dsg3), a desmosomal adhesion protein on epidermal keratinocytes, cause loss of epidermal cell adhesion. Objectives: To assess the clinical applicability of an innovative nanoparticle platform for the induction of immune tolerance exploiting the natural tolerance potential of liver sinusoidal endothelial cells. An open-label first-in-human study was conducted with TPM203, a mixture of four nanoparticle-coupled immunodominant Dsg3 T-cell peptides. Methods: The efficacy and mechanism of action of TPM203 were first tested in a humanized HLA-DRB1*0402-transgenic PV mouse model. In the clinical phase I trial, TPM203 was administered intravenously in patients with PV with no-to-moderate disease activity in single ascending and multiple doses (three doses of TPM203 two weeks apart). Primary endpoints included safety and tolerability. As a secondary endpoint, pharmacokinetics were assessed. Exploratory endpoints comprised changes in Dsg3-specific and bulk T- and B-cell frequencies, anti-Dsg3 IgG levels and autoantibody-induced keratinocyte dissociation. The trial was registered with EudraCT (2019-001727-12). Results: In the PV mouse model, two administrations of TPM203 significantly reduced anti-Dsg3 IgG. On the cellular level, TPM203 led to a significant decrease in CD4+ T cells in the spleen, accompanied by increased frequencies of regulatory T (Treg) cells. In the clinical trial, the 17 patients with PV enrolled across single- and multiple-dose groups did not experience any serious or severe adverse events, or treatment-related PV worsening. Pharmacokinetics confirmed rapid TPM203 clearance from the circulation. Significant TPM203-induced modulations in bulk lymphocyte subsets included an increase in Treg cells, and reductions in T helper 17.1 and CD27+ memory B cells, when dose groups were combined for analysis. Dsg3-specific T cells were found to be significantly reduced at week 8 following single administration of TPM203. Anti-Dsg3 IgG levels trended downward in the three lower single ascending dose groups, while IgG-induced keratinocyte-dissociating capacity was significantly reduced after multiple doses. Conclusions: Administered for the first time in humans, TPM203 was shown to be a safe and well-tolerated nanoparticle-based therapeutic approach with the potential to promote tolerance induction in PV, justifying further clinical development in this and other autoimmune diseases. An author video to accompany this article is available online.
- 1 October 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 46 (10) , 649-689
Diagnose und Therapie der Bienen- und Wespengiftallergie
- 1 October 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 46 (10) , 649-689
Diagnose und Therapie der Bienen- und Wespengiftallergie
- Open Access
- 1 January 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 7 (01) , 211-218
Allergen immunotherapy of insect venom allergy: Almost 100 years old, but steadily updated
Allergen immunotherapy (AIT) with Hymenoptera venom (HV) is an extraordinary efficient, causal therapy of allergy against insect venom, which looks back on an almost 100-year long history. Untreated patients with HV allergy can develop serious, potentially lethal sting reactions. Before starting AIT with HV, indication and contraindications, the presence of co-morbidities and intake of concomitant medications as well as individual risk factors have to be carefully checked. Application of HV-AIT also entails an individually adapted proceeding in case of undesired adverse events or initial failure to induce tolerance, as the final goal has to be the successfull development of immunologic protection against anaphylactic sting reactions.
- 1 January 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 7 (01) , 211-218
Open AccessAllergen immunotherapy of insect venom allergy: Almost 100 years old, but steadily updated
Allergen immunotherapy (AIT) with Hymenoptera venom (HV) is an extraordinary efficient, causal therapy of allergy against insect venom, which looks back on an almost 100-year long history. Untreated patients with HV allergy can develop serious, potentially lethal sting reactions. Before starting AIT with HV, indication and contraindications, the presence of co-morbidities and intake of concomitant medications as well as individual risk factors have to be carefully checked. Application of HV-AIT also entails an individually adapted proceeding in case of undesired adverse events or initial failure to induce tolerance, as the final goal has to be the successfull development of immunologic protection against anaphylactic sting reactions.
- Open Access
- 7 September 2022
- Published by Elsevier in JID Innovations
- Vol. 3 (1) , 100155
Isolation of Lymphocytes from Human Skin and Murine Tissues: A Rapid and Epitope-Preserving Approach
- 7 September 2022
- Published by Elsevier in JID Innovations
- Vol. 3 (1) , 100155
Open AccessIsolation of Lymphocytes from Human Skin and Murine Tissues: A Rapid and Epitope-Preserving Approach